Biopreparedness uniquely relies upon drugs. However, the globalization of drug manufacturing and supply has created challenges to ensuring open and available access to these products. The heparin case illustrates the challenges of offshore and onshore efforts to secure the drugs necessary to address naturally-occuring and human-sourced biological agents. Economic incentives, international diplomacy, and alternative sourcing must be addressed to ensure the US can be bioprepared and respond effectively to biowarfare and biological agents.